Open Actively Recruiting

Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults with Gorlin Syndrome

About

Brief Summary

The aim of this clinical study is to find out how well Patidegib Gel 2% works in preventing new basal cell carcinomas (BCCs) developing on the face of adults with Gorlin syndrome, and how safe Patidegib Gel 2% is to use.

People who take part will apply either Patidegib Gel 2% or a Vehicle Gel (with no active drug substance) to their face twice a day for a year (12 months). The number of new BCCs on the face will be compared between those who used Patidegib Gel 2% or Vehicle Gel after 12 months.

Primary Purpose
Prevention
Study Type
Interventional
Phase
Phase 3

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
N/A

Key Inclusion Criteria:

  • The subject must be at least 18 years old at the Screening Visit.
  • The subject must be confirmed to have a PTCH1 mutation.
  • The subject must have at least 10 BCCs on the face at Randomization (Baseline/Day 1).
  • The subject must be willing to abstain from application of any non-study topical medication (prescription or over the counter) to their facial skin for the duration of the trial, except as prescribed by the investigator.

Key Exclusion Criteria:

  • The subject has used topical treatment to the face or systemic therapies that might interfere with the evaluation of the study Investigational Product (IP).
  • The subject is known to have hypersensitivity to any of the ingredients in the IP formulation.
  • The subject has uncontrolled systemic disease.
  • The subject has been treated for invasive cancer within the past 5 years excluding chronic lymphocytic leukemia Stage 0, non-melanoma skin cancer, successfully treated melanoma in situ and Stage I melanoma, Stage I cervical cancer, or ductal carcinoma in situ of the breast.
  • Inefficacy of previous Hedgehog inhibitor therapy.

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Share:
Study Stats
Protocol No.
24-5043
Category
Melanoma (Skin Cancer)
Contact
April Armstrong
Location
  • UCLA Santa Monica
  • UCLA Westwood
For Providers
NCT No.
NCT06050122
For detailed technical eligibility, visit ClinicalTrials.gov.